Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.56 |
| ▸ | ARG2 | P78540 | 5/20 | 0.50 |
| ▸ | ARG1 | P05089 | 3/20 | 0.50 |
| ▸ | NOS2 | P35228 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | GRM8 | O00222 | 1/20 | 0.48 |
| ▸ | GRM6 | O15303 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.48 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2722969 | 1.00 | GSR (0.56) | GSRARG2ARG1NOS2CYP1A2 | |
| SCHEMBL79859 | 1.00 | GSR (0.56) | GSRARG2ARG1NOS2CYP1A2 | |
| SCHEMBL30463729 | 0.98 | GSR (0.54) | GSRARG2ARG1NOS2CYP1A2 | |
| SCHEMBL259006 | 0.93 | GSR (0.59) | GSRARG2ARG1NOS2CYP1A2 | |
| SCHEMBL3423971 | 0.93 | GSR (0.59) | GSRARG2ARG1NOS2CYP1A2 | |
| SCHEMBL17262412 | 0.93 | GSR (0.59) | GSRARG2ARG1NOS2CYP1A2 | |
| SCHEMBL29958570 | 0.91 | GSR (0.57) | GSRARG2ARG1NOS2CYP1A2 | |
| SCHEMBL2599185 | 0.91 | GSR (0.57) | GSRARG2ARG1NOS2CYP1A2 | |
| Ornithine SCHEMBL10560893 | 0.88 | GSR (0.64) | GSRARG2ARG1NOS2CYP1A2 | |
| Lysine SCHEMBL4956653 | 0.86 | GSR (0.74) | GSRARG2ARG1NOS2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 735 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230115432-A1 | Methods and Apparatuses for Early Diagnosis of Lung Infection Acuity | DIAGNOSE EARLY, INC. | 2023-04-13 | — | — | US | claimed |
| CN-115932131-A | Enrichment and identification method of carbonylation protein in muscle tissue | 南京农业大学 | 2023-04-07 | — | — | CN | claimed |
| US-20230101362-A1 | RNA STABILIZATION | TEAM MEDICAL LLC | 2023-03-30 | — | — | US | claimed |
| EP-4127212-A1 | METHODS AND APPARATUSES FOR EARLY DIAGNOSIS OF LUNG INFECTION ACUITY | Diagnose Early, Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| CN-113189214-B | Large yellow croaker proliferation and releasing molecular marker and screening method thereof | 宁波大学 | 2022-06-21 | — | — | CN | claimed |
| CN-114377144-A | PH/active oxygen dual-responsive supramolecular polypeptide prodrug nanoparticle | 南通大学 | 2022-04-22 | — | — | CN | claimed |
| WO-2021195489-A1 | METHODS AND APPARATUSES FOR EARLY DIAGNOSIS OF LUNG INFECTION ACUITY | DIAGNOSE EARLY, INC. (US) | 2021-09-30 | — | — | WO | claimed |
| US-20190072514-A1 | SYSTEM AND METHOD FOR DETECTING LYSYL OXIDASE-LIKE 2 PROTEIN (LOXL2) AND BREAST CANCER | CASE WESTERN RESERVE UNIVERSITY | 2019-03-07 | — | — | US | claimed |
| CN-106526156-B | A method of detection, screening and identification syndrome of deficiency of kidney yang metabolism biological marker | 王喜军 | 2018-12-04 | — | — | CN | claimed |
| EP-2901163-B1 | METHOD FOR DETECTING LYSYL OXIDASE-LIKE 2 PROTEIN (LOXL2) AND BREAST CANCER | UNIV CASE WESTERN RESERVE (US) | 2018-11-28 | — | — | EP | claimed |
| US-20150253280-A1 | SYSTEM AND METHOD FOR DETECTING LYSYL OXIDASE-LIKE 2 PROTEIN (LOXL2) AND BREAST CANCER | CASE WESTERN RESERVE UNIVERSITY | 2015-09-10 | — | — | US | claimed |
| EP-2901163-A1 | SYSTEM AND METHOD FOR DETECTING LYSYL OXIDASE-LIKE 2 PROTEIN (LOXL2) AND BREAST CANCER | Case Western Reserve University (US) | 2015-08-05 | — | — | EP | claimed |
| CN-104704372-A | System and method for detecting lysyl oxidase-like 2 protein (LOXL2) and breast cancer | UNIV CASE WESTERN RESERVE | 2015-06-10 | — | — | CN | claimed |
| US-7572607-B2 | Polypeptides and biosynthetic pathways for the production of monatin and its precursors | CARGILL, INCORPORATED (US) | 2009-08-11 | — | — | US | claimed |
| EP-1375510-B1 | Modification of collagenous materials and medical treatment, diagnosis and monitoring of fibrotic conditions | TNO (NL) | 2008-06-04 | — | — | EP | claimed |
| US-20060141568-A1 | Modification of collagenous materials and medical treatment, diagnosis and monitoring of fibrotic conditions | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2006-06-29 | — | — | US | claimed |
| US-7045600-B2 | Modification of collagenous materials and medical treatment, diagnosis and monitoring of fibrotic conditions | NEDERLANDSE ORGANISATIE VOOR TOEGEPASTNATUUR-WETENSCHAPPELIJK ONDREZOEK TNO (NL) | 2006-05-16 | — | — | US | claimed |
| US-20050244937-A1 | Contacting a polypeptide with tryptophan or 2-hydroxy 2-(indol-3-ylmethyl)-4-keto glutaric acid to facilitate a conversion of tryptophan to indole-3-pyruvate, a conversion of 2-hydroxy 2-(indol-3-ylmethyl)-4-keto glutaric acid to 2-Hydroxy-2-(indol-3-ylmethyl)-4-aminoglutaric acid (monatin) | CARGILL, INC. | 2005-11-03 | — | — | US | claimed |
| EP-1375510-A1 | Modification of collagenous materials and medical treatment, diagnosis and monitoring of fibrotic conditions | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO (NL) | 2004-01-02 | — | — | EP | claimed |
| US-20030219852-A1 | Modification of collagenous materials and medical treatment, diagnosis and monitoring of fibrotic conditions | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST- NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2003-11-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050244937-A1 | Contacting a polypeptide with tryptophan or 2-hydroxy 2-(indol-3-ylmethyl)-4-keto glutaric acid to facilitate a conversion of tryptophan to indole-3-pyruvate, a conversion of 2-hydroxy 2-(indol-3-ylmethyl)-4-keto glutaric acid to 2-Hydroxy-2-(indol-3-ylmethyl)-4-aminoglutaric acid (monatin) | AADAT, KYAT3, MON2 | GSR 1968/4885ARG2 253/4885ARG1 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.